1. Home
  2. MED vs CHRS Comparison

MED vs CHRS Comparison

Compare MED & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$11.91

Market Cap

120.6M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.39

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MED
CHRS
Founded
1980
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.6M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MED
CHRS
Price
$11.91
$1.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$16.50
$4.02
AVG Volume (30 Days)
274.7K
959.3K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
1.34
Revenue
$429,695,000.00
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.29
P/E Ratio
$491.07
$2.58
Revenue Growth
N/A
152.07
52 Week Low
$10.36
$0.71
52 Week High
$18.59
$1.89

Technical Indicators

Market Signals
Indicator
MED
CHRS
Relative Strength Index (RSI) 51.91 53.23
Support Level $10.72 $1.31
Resistance Level $12.40 $1.41
Average True Range (ATR) 0.40 0.09
MACD 0.13 0.02
Stochastic Oscillator 60.00 77.34

Price Performance

Historical Comparison
MED
CHRS

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: